Neuraxis amends Series B Preferred terms: extends dividends, increases authorized shares, revises voting rights

Neuraxis, INC

Increased authorized Series B Preferred shares from 4,000,000 to 5,000,000.
Extended 8.5% annual dividend right by 18 months, now through December 31, 2026.
Amended voting rights: each Series B share votes equal to common shares convertible at $3.80 per share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.